Pharmacodynamic Exposure–Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH

Documenti analoghi

• Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia
  di: Matthew W. Hruska, et al.
  Pubblicazione: (2024)
• Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib
  di: Allison Dunn, et al.
  Pubblicazione: (2024)
• Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics
  di: Kevin. V. Tobin, et al.
  Pubblicazione: (2026)
• Response to Letter to the Editor from Madhuri Tribhuvan and Shashikant N. Phatke
  di: Kevin. V. Tobin, et al.
  Pubblicazione: (2026)
• Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids
  di: Matthew W. Hruska, et al.
  Pubblicazione: (2024)